CONFERENCE COVERAGE SERIES
Clinical Trials on Alzheimer's Disease 2012
Grimaldi Forum Convention Center, Monte Carlo, Monaco
29 – 31 October 2012
CTAD: Turning the Ship Around Toward Early Trials
The 5th Clinical Trials in Alzheimer’s Disease conference showcased a field trying to steer therapy development out of the doldrums of the past decade and into swifter waters...
CTAD: New Data on Sola, Bapi, Spark Theragnostics Debate
The 5th Clinical Trials in Alzheimer’s Disease conference offered new data from ongoing analyses of the Phase 3 programs on solanezumab and bapineuzumab...
CTAD: Regulatory Science Gains Prominence in AD Research
At the 5th Clinical Trials in Alzheimer’s Disease conference in Monaco, six talks covered "regulatory science"...
CTAD: Adaptive Antibody Trial to Try Bayesian Statistics
Time to Adapt: Alzheimer trialists are poised to take a plunge into the depths of Bayesian statistics with a new antibody phase 2 trial...
CTAD: ApoE Carriers Sought for Trial of NSAID Derivative
The conference featured a new Phase 2 program that uses genetics to enrich an MCI population for an early-stage therapeutic trial...
CTAD: EEG Gains Luster as More Trials Incorporate Biomarkers
The 5th Clinical Trials in Alzheimer’s Disease conference showcased the field’s pressing need for biomarkers as outcome measures...
CTAD: AD Treatment Might Not Lower Healthcare Costs
Researchers modeled a hypothetical disease-modifying AD treatment and found that the expense of the drug could more than offset the money saved in nursing home care...